Biotech Values

[Mufaso]

NRBO - They are going the "Hormone" route as oxyntomodulin is one of the many well known hormones involved in appetite. It is an interesting hormone to go after as one of the properties this hormone exhibits is that it "inhibits gastric acid secretion".

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777281/

 
 Hunger	  Hormone	   Primary location of production	Receptors	Action 
 Satiety  Oxyntomodulin	   Distal ileum and colon	       GLP-1 receptor	Inhibiting gastric acid secretion, decreasing gastric emptying, and decreasing pancreatic enzyme secretion 
 

Commons sense would tell you this would theoretically increase tolerability. It certainly is worth investigating and I would contend tolerability will ultimately decide the winners (note plural) in the obesity arena.

Other thoughts:

• The hormone space is “hot”. (See #msg-173694133. ) Kallyope is in testing of other hormones and I've speculated that PFE's compound with an undisclosed MOA is likely targets one of these hormones involved in appetite besides GLP1. (see #msg-173593650)
  
  
• NeuroBo's drug is being dosed SubQ in ph1 and oxyntomodulin is a peptide. It is unlikely this drug could be delivered/effective as an oral agent.